会 议 简 介
2011年美国高血压学会（ASH）科学年会将于2011年5月21～24日在美国纽约举行，本届年会将以“青少年肥胖的流行趋势及其心血管危险降低”为主题，在以下三个领域展开研讨：
•高血压病理学
•高血压的转化问题
•高血压的治疗
有关“把基础研究和应用研究成果进一步转化为有效的高血压防治策略”的会议内容将是本届年会的亮点。
美国高血压协会第26届科学年会（ASH 2011）会 议 议 程
5月23日
Satellite Symposium
6:00 AM – 7:30 AM ? Trianon Ballroom ? Third Floor
The Role of Beta-Blockers in Hypertension:A Healthy Debate
Chairman: Jan N. Basile， MD， FASH， Charleston， SC
Learning Objectives: Describe the differences and similarities among agents within the beta-blocker class of antihypertensive agents Summarize the results of key clinical trials investigating beta blockade in African American，
Hispanic， and Asian patient populations List reasons why beta-blockers should or should not be used as first line or second step therapy for hypertension
Program Agenda:
6:00 AM Welcome
Overview of Program Learning Objectives Audience Response System (ARS)
Jan N. Basile， MD， FASH， Chairman
6:05 AM The Class Effect With Beta-Blockers: Does One Size Fit All?
Addison A. Taylor， MD， PhD， FASH，Houston， TX
6:25 AM Beta-Blockers and Ethnicity: What Do We Really Know?
Henry A. Punzi， MD， Dallas， TX
6:45 AM Debate: Beta-Blockers Are Appropriate for First Line or Second Step Therapy in Patients With Hypertension
AGREE: William H. Frishman， MD，Valhalla， NY DISAGREE: Franz H. Messerli， MD， FASH， New York， NY
7:15 AM Faculty Panel Discussion With Questions From the Audience
Jan N. Basile， MD， FASH， Moderator
7:30 AM Review of Program Learning Objectives and Closing Remarks
Jan N. Basile， MD， FASH， Moderator
Sessions
8:00 AM – 10:05 AM ? Mercury Ballroom ? Third Floor
Off-Target Cardiovascular Effects of Non-Cardiovascular Drugs
Co-Chairs: Franz H. Messerli， MD， FASH， New York， NY and Suzanne Oparil， MD， FASH， Birmingham， AL
8:00 AM Anti-VEGF and Other Chemotherapeutic Agents
Rhian M. Touyz， MD， PhD， Ottawa， Canada
8:20 AM Non-Steroidal Anti-Inflammatory Drugs
Raymond C. Harris， MD， Nashville， TN
8:40 AM PDE5 Inhibitors and Organic Nitrates
David J. Webb， MD， Edinburgh， United Kingdom
9:00 AM PPAR Agents
Julio A. Panza， MD， Washington， DC
Original Communications
9:20 AM OR-15: Effects on Ambulatory Blood Pressure of Adding Low-Dose Aspirin at Bedtime in Subjects
with Treated Hypertension
Ramon C. Hermida， University of Vigo， Vigo， ES.
9:35 AM OR-16: Cardio-Metabolic Effects of Acute and Sub-Acute Exposures to Ambient Levels of Fine
Particulate Matter Air Pollution
Robert D. Brook，1 Robert L. Bard，1 J. Timothy Dvonch，1 Masako Morishita，1 Niko Kaciroti，1 Sanjay Rajagopalan.2 1University of Michigan， US; 2Ohio State University， US.
9:50 AM OR-17: Impact of Nonsteroidal Anti-Inflammatory Drugs on Nocturnal Blood Pressure
W. B. White?，1 L. Lavange，2 A. Marquis.2 1University of Connecticut School of Medicine， Farmington， CT， US;
2University of North Carolina at Chapel Hill， Chapel Hill， NC， US.
Sessions
8:00 AM – 10:00 AM ? East Ballroom ? Third Floor
New Insights into the Role of Uric Acid in Hypertension
Co-Chairs: Richard J. Johnson， MD， Denver， CO and Andrew Whelton， MD， Baltimore， MD
8:00 AM Fructose-Obesity-Uric Acid Link
Richard J. Johnson， MD
8:25 AM Oxidative Stress and Impact of Uric Acid
Allan D. Struthers， MD， Dundee， United Kingdom
8:40 AM Urate-Lowering and Blood Pressure Response
Daniel I. Feig， MD， PhD， Houston， TX
Original Communications
9:00 AM OR-18: Associations of Uric Acid with Asymmetric
Dimethylarginine， L-arginine and Arterial Stiffening in Hypertension
K. Dimitriadis， C. Tsioufis， A. Aggelis， S. Kyvelou，E. Stefanadi， L. Lioni， D. Flessas， C. Stefanadis. Hippokration Hospital， Athens， GR.
9:15 AM OR-19: Epoxyeicosatrienoic Acid Agonist Attenuates Adipogenesis Derived from Mesenchymal Stem Cells
Via Heme Oxygenase-PPARg Pathways
DongHyun Kim，1 Luca Vanella，1 Nitin Puri，1 Michal L. Schwartzman，2 John R. Falck，3 Komal Sodhi，1 Nader G.
Abraham.1 1University of Toledo College of Medicine，Toledo， OH， US; 2New York Medical College， Valhalla，
NY， US; 3University of Texas Southwestern Medical Center， Dallas， TX， US.
9:30 AM OR-20: Effect of Allopurinol on Blood Pressure: A Systematic Review
Vikram Agarwal，1 Nidhi Hans，2 Franz Messerli.1 1St. Luke’s-Roosevelt Hospital Center， NY， US; 2Harvard School of Public Health， MA， US.
Sessions
8:00 AM – 10:00 AM ? West Ballroom ? Third Floor
Devices and Surgical Ablation for Refractory Hypertension
Co-Chairs: Domenic A. Sica， MD， Richmond， VA and
Ronald G. Victor， MD， Los Angeles， CA
8:00 AM How to Evaluate and Choose the Appropriate Patient?
Henry Krum， MBBS， PhD， Melbourne， Australia
8:20 AM Renal Nerve Ablation
Roland E. Schmieder， MD， Erlangen， Germany
8:40 AM Carotid Baroreceptor Manipulation
John D. Bisognano， MD， PhD， FASH， Rochester， NY
Original Communications
9:00 AM OR-21: True Resistant Hypertension: Optimal Cut-Off Ambulatory Blood Pressure Level for Diagnosis
and Effect of Spironolactone
Jose A. Garcia?Donaire， Julian Segura， Cesar Cerezo，
Luis M. Ruilope. Hospital 12 de Octubre， Madrid， ES.
9:15 AM OR-22: Individualized Programming Demonstrates Feasibility of Unilateral Approach to Delivery of
Baroreflex Activation Therapy?
Domenic Sica，1 John Bisognano，2 Mitra Nadim，3 Luis Sanchez，4 George Bakris.5 1Virginia Commonwealth
University， Richmond， VA， US; 2University of Rochester， Rochester， NY， US; 3University of Southern
California， Los Angeles， CA， US; 4Washington University， St. Louis， MO， US; 5University of Chicago，Chicago， IL， US.
9:30 AM OR-23: The Efficacy of Adding the Direct Renin Inhibitor Aliskiren on the Patients with Resistant Hypertension (55% Had Chronic Kidney Disease)– Subgroup Analysis on Different Levels of Plasma Renin Activity Fumitoshi Satoh， Ryo Morimoto， Masataka Kudo，Yoshitugu Iwakura， Yoshikiyo Ono， Sadayoshi Ito.Tohoku University Hospital， Sendai， JP
9:45 AM OR-24: Exploring the Prevalence of Resistant Hypertension in a Large Ethnically Diverse Hypertensive Population
Simran Bhandari， In Lu Liu， Jiaxiao Shi， FedericoCalara， Scott Rasgon， John Sim. Kaiser Permanente
Los Angeles Medical Center， Los Angeles， CA， US.
Sessions
8:30 AM – 10:00 AM ? Trianon Rendezvous ? Third Floor
The Kidney Early Evaluation Program (KEEP):A New Longitudinal Dimension for a New Decade Held in Partnership with the National Kidney Foundation (NKF)
Co-Chairs: George L. Bakris， MD， FASH， Chicago， IL and Joseph A. Vassalotti， MD， New York， NY
8:30 AM KEEP: CKD Screening Program Overview
George L. Bakris， MD， FASH
8:52 AM KEEP: Longitudinal Preliminary Results
Joseph A. Vassalotti， MD
9:14 AM KEEP: Experience with the CKD-EPI Equation
Lesley A. Stevens， MD， MS Bos